Studies have found that CyPass Micro-Stent implantation to treat open-angle glaucoma (OAG) in conjunction with cataract surgery, resulted in minimal complications and reduced IOP and IOP-lowering medication used at 12 months postoperatively.
CyPass Micro-Stent is a novel device designed to lower IOP when implanted as part of a microinvasive glaucoma surgery procedure. It is implanted into the supraciliary space to facilitate suprachoroidal aqueous outflow. The procedure is ab interno, minimally invasive, and designed to be less traumatic than full-thickness penetration procedures.
Dr. Magda Rau, an investigator of the multicenter European CyPass Clinical Experience (CyCLE) study, an ongoing, openlabel, interventional, multicenter study of the safety and efficacy of microstent implantation in patients with OAG, first implanted Alcon’s CyPass in 2009 and told OSN Italy meeting delegates that she was “very satisfied” with the results. She is also conducting her own prospective study on CyPass implantation at her clinic.
Her results on 33 patients, 24 undergoing combined surgery and nine undergoing CyPass implantation as a stand-alone procedure, are comparable with those of the CyCLE study.
The procedure is ab interno, minimally invasive, and designed to be less traumatic than full-thickness penetration procedures
“The reduction of intraocular pressure after three years is still 28 per cent to 30 per cent, with a greater reduction in patients undergoing both cataract and CyPass surgery. The mean number of medications is down from approximately two to one,” Dr. Rau told Healio.
For more about CyPass read miophthalmology, page 37, August 2017
www.healio.com/ophthalmology/glaucoma/news/online, 6 June 2017